Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03859050 · ClinicalTrials.gov registry record · NA
Alveolar Macrophage Programming Following Endotoxin Exposure
A NA study of ARDS, Human, sponsored by National Jewish Health.
- Recruiting
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT03859050 is a NA study of ARDS, Human that is actively recruiting participants, run by National Jewish Health. The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03859050, a NA study of ARDS, Human, is actively recruiting participants, sponsored by National Jewish Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The histologic hallmarks of lung inflammation include accumulation of inflammatory cells in the airspaces and interstitium, injury to alveolar epithelial and endothelial cells, loss of epithelial-capillary integrity and accumulation of edema fluid in the interstitium and airspaces. Accordingly, for alveolar repair to occur inflammation must be halted, debris and inflammatory cells removed, injured tissue cells replaced, and capillary barrier function re-established. Macrophages are key players in all of these. Here the investigators hypothesize that resident alveolar macrophages and recruited macrophages serve completely different functions, acting independently (i.e. division of labor) yet cooperatively (synergism).
Conditions Studied
Interventions
- OTHER bronchoscopy with intrabronchial administration of lipopolysaccharide
Study Locations (1)
Colorado
- National Jewish Health - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-03-18 |
| Est. Completion | 2032-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03859050
The ClinicalTrials.gov registry entry for NCT03859050 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with ARDS, Human appearing as the primary indexed condition, and to 1 intervention - of which bronchoscopy with intrabronchial administration of lipopolysaccharide is the first listed.
NCT03859050 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT03859050 about?
NCT03859050 is a clinical study titled "Alveolar Macrophage Programming Following Endotoxin Exposure". The histologic hallmarks of lung inflammation include accumulation of inflammatory cells in the airspaces and interstitium, injury to alveolar epithelial and endothelial cells, loss of epithelial-capillary integrity and accumulation of edema fluid in the interstitium and airspaces. Accordingly, for ...
What is the current status of trial NCT03859050?
This trial is currently recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2019-03-18. Estimated completion is 2032-07.
What conditions does trial NCT03859050 study?
This clinical trial studies the following conditions: ARDS, Human.
What interventions are being tested in trial NCT03859050?
The interventions under investigation include: bronchoscopy with intrabronchial administration of lipopolysaccharide (OTHER).
Who is sponsoring clinical trial NCT03859050?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03859050 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ARDS, Human
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.